Prodia Diagnostic Line is trading 10.3% down at IDR 296 after reporting a net loss of Rp8.84 billion in the first half of 2026, sharply disappointing investor expectations.
- Revenue plummeted 52% year-on-year, signaling deteriorating fundamentals that have triggered heavy selling pressure.
- The stock's outsized move comes despite a generally supportive backdrop for the broader healthcare sector, highlighting company-specific weakness.